<DOC>
	<DOC>NCT01999322</DOC>
	<brief_summary>This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to evaluate compatibility and safety of FIAsp (faster-acting insulin aspart) and insulin aspart (NovoRapidÂ®) with an external continuous subcutaneous insulin infusion (CSII) system in adult subjects with type 1 diabetes.</brief_summary>
	<brief_title>A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<criteria>Male or female, age at least 18 years at the time of signing inform consent Type 1 diabetes mellitus (diagnosed clinically) for at least 12 months at the time of screening (Visit 1) Currently treated with insulin aspart, insulin lispro or insulin gluisine for at least 3 months prior to screening (Visit 1) Using an external CSII system for the previous 6 months prior to screening (Visit 1) HbA1c (glycosylated haemoglobin) below or equal to 9.0% as assessed by central laboratory Body Mass Index (BMI) 20.035.0 kg/m^2 History of diabetic ketoacidosis (DKA) episodes requiring hospitalization within 6 months prior to screening (Visit 1) History of abscess at the infusion site within 6 months prior to screening (Visit 1) Hypoglycaemic unawareness as judged by the Investigator or history of severe hypoglycaemic episodes requiring hospitalization within the last 6 months prior to screening (Visit 1)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>